Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Konstantinos Arnaoutakis

Concepts (129)

Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Lung Neoplasms
6
2024
645
1.560
Why?
Carcinoma, Non-Small-Cell Lung
4
2024
175
1.460
Why?
Protein Kinase Inhibitors
2
2024
234
1.090
Why?
Hematology
4
2024
23
0.990
Why?
Medical Oncology
4
2024
97
0.810
Why?
Piperidines
1
2024
99
0.790
Why?
Pyrazoles
2
2024
123
0.590
Why?
Neoplasms
4
2018
1335
0.590
Why?
Adenocarcinoma, Clear Cell
1
2017
35
0.510
Why?
Bone Marrow
2
2016
359
0.500
Why?
Leukemia, Promyelocytic, Acute
1
2016
11
0.470
Why?
Anemia, Aplastic
1
2016
10
0.470
Why?
Pancytopenia
1
2016
37
0.460
Why?
Communication
2
2016
263
0.440
Why?
Protein-Tyrosine Kinases
1
2015
87
0.420
Why?
Physician-Patient Relations
1
2016
146
0.420
Why?
Proto-Oncogene Proteins
1
2015
150
0.420
Why?
Bone Marrow Neoplasms
1
2014
13
0.410
Why?
Seminoma
1
2013
4
0.410
Why?
Pyridines
1
2015
135
0.400
Why?
Hodgkin Disease
1
2014
45
0.400
Why?
Biopsy, Fine-Needle
1
2014
104
0.400
Why?
Testicular Neoplasms
1
2013
46
0.390
Why?
Paralysis
1
2013
9
0.390
Why?
Spinal Cord Neoplasms
1
2013
14
0.390
Why?
Lymphoma, Large B-Cell, Diffuse
1
2013
110
0.360
Why?
Aged
12
2024
10430
0.330
Why?
Antineoplastic Agents
4
2024
1232
0.330
Why?
Bronchial Neoplasms
1
2009
5
0.310
Why?
Lymphoma, B-Cell, Marginal Zone
1
2009
24
0.300
Why?
Fellowships and Scholarships
2
2022
124
0.290
Why?
Humans
23
2024
53246
0.280
Why?
Female
12
2024
28792
0.250
Why?
Middle Aged
8
2024
13422
0.240
Why?
Foreign Medical Graduates
1
2024
7
0.220
Why?
Carbazoles
1
2024
17
0.210
Why?
Sulfones
1
2024
24
0.210
Why?
Lactams
1
2024
28
0.210
Why?
Aminopyridines
1
2024
19
0.210
Why?
Treatment Outcome
5
2024
5597
0.210
Why?
Neoplasm Metastasis
2
2016
237
0.210
Why?
Tomography, X-Ray Computed
3
2014
1183
0.190
Why?
Pyrimidines
1
2024
206
0.190
Why?
Antineoplastic Combined Chemotherapy Protocols
4
2016
1043
0.180
Why?
Radiography
2
2013
476
0.180
Why?
Male
9
2024
27444
0.180
Why?
Retrospective Studies
4
2024
6821
0.150
Why?
Adult
6
2024
14541
0.150
Why?
Integrative Medicine
1
2018
11
0.130
Why?
Terminal Care
1
2018
37
0.130
Why?
Patients
1
2018
52
0.130
Why?
Quality Improvement
2
2016
230
0.130
Why?
Keratins
1
2017
27
0.130
Why?
DNA, Neoplasm
1
2018
146
0.130
Why?
Doxorubicin
2
2017
248
0.130
Why?
Nanotubes
1
2017
17
0.130
Why?
Qualitative Research
2
2018
384
0.130
Why?
Oncogene Proteins, Fusion
1
2017
62
0.130
Why?
Drug Carriers
1
2017
68
0.130
Why?
Silver
1
2017
49
0.130
Why?
Neoplasm, Residual
1
2018
171
0.120
Why?
Attitude to Health
1
2018
193
0.120
Why?
Gold
1
2017
81
0.120
Why?
Constipation
1
2016
37
0.120
Why?
Mastication
1
2016
5
0.120
Why?
Education, Medical
1
2018
111
0.120
Why?
Learning
1
2018
156
0.120
Why?
Chemotherapy, Adjuvant
2
2013
122
0.120
Why?
Pyrroles
1
2016
74
0.120
Why?
Antibodies, Monoclonal
2
2017
477
0.120
Why?
Quality Assurance, Health Care
1
2016
146
0.120
Why?
Salvage Therapy
2
2013
138
0.110
Why?
Carcinoma, Renal Cell
1
2016
112
0.110
Why?
Quality of Health Care
1
2016
189
0.110
Why?
Membrane Proteins
1
2017
333
0.110
Why?
Computer Simulation
1
2016
290
0.110
Why?
Kidney Neoplasms
1
2016
181
0.110
Why?
Immunohistochemistry
1
2017
975
0.110
Why?
Factor VIII
1
2014
24
0.110
Why?
ADAM Proteins
1
2014
21
0.100
Why?
Purpura, Thrombotic Thrombocytopenic
1
2014
16
0.100
Why?
Plasma Exchange
1
2014
25
0.100
Why?
Reed-Sternberg Cells
1
2014
2
0.100
Why?
HIV Seronegativity
1
2014
3
0.100
Why?
Orchiectomy
1
2013
38
0.100
Why?
Scrotum
1
2013
31
0.100
Why?
Pain
1
2016
353
0.100
Why?
Indoles
1
2016
280
0.100
Why?
Bronchoscopy
1
2014
78
0.100
Why?
Fatal Outcome
1
2013
193
0.090
Why?
Diagnosis, Differential
1
2016
1038
0.090
Why?
Positron-Emission Tomography
1
2014
299
0.090
Why?
Biopsy
1
2014
600
0.090
Why?
Aged, 80 and over
3
2014
3495
0.080
Why?
Analgesics, Opioid
1
2016
622
0.080
Why?
Neoplasm Recurrence, Local
1
2013
647
0.080
Why?
Nausea
1
2008
43
0.070
Why?
Morpholines
1
2008
64
0.070
Why?
Vomiting
1
2008
71
0.070
Why?
Survival Analysis
1
2009
659
0.070
Why?
Immunotherapy
1
2009
266
0.070
Why?
Neoplasm Staging
1
2009
774
0.060
Why?
Patient Satisfaction
2
2016
292
0.050
Why?
Prognosis
1
2009
2118
0.050
Why?
Societies, Medical
1
2024
207
0.050
Why?
Accreditation
1
2022
63
0.040
Why?
United States
2
2024
5413
0.040
Why?
Education, Medical, Graduate
1
2022
219
0.040
Why?
Coated Materials, Biocompatible
1
2017
34
0.030
Why?
Spectrum Analysis, Raman
1
2017
42
0.030
Why?
Genotype
1
2018
563
0.030
Why?
Molecular Targeted Therapy
1
2017
138
0.030
Why?
Young Adult
2
2016
4514
0.030
Why?
Cell Survival
1
2017
600
0.030
Why?
Autoantibodies
1
2014
120
0.020
Why?
Cell Line, Tumor
1
2017
1470
0.020
Why?
Immunosuppressive Agents
1
2014
253
0.020
Why?
Combined Modality Therapy
1
2014
640
0.020
Why?
Carcinoma, Small Cell
1
2010
26
0.020
Why?
SEER Program
1
2010
106
0.020
Why?
Antiemetics
1
2008
32
0.020
Why?
Cyclophosphamide
1
2008
178
0.020
Why?
Drug Therapy, Combination
1
2008
405
0.020
Why?
Dexamethasone
1
2008
429
0.020
Why?
Dose-Response Relationship, Drug
1
2008
1367
0.010
Why?
Adolescent
1
2016
6912
0.010
Why?
Prospective Studies
1
2008
2412
0.010
Why?
Time Factors
1
2008
2992
0.010
Why?
Breast Neoplasms
1
2008
1223
0.010
Why?
Arnaoutakis's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description